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Metastasis to the breast from an adenocarcinoma of
the lung with extensive micropapillary component:











Breast metastasis from extra-mammary malignancy is rare. Based on the literature an incidence of 0.4-1.3% is
reported. The primary malignancies most commonly metastasizing to the breast are leukemia-lymphoma, and
malignant melanoma. We present a case of metastasis to the breast from a pulmonary adenocarcinoma, with
extensive micropapillary component, diagnosed concomitantly with the primary tumor. A 73-year-old female pre-
sented with dyspnea and dry cough of 4 weeks duration and a massive pleural effusion was found on a chest
radiograph. Additionally, on physical examination a poorly defined mass was noted in the upper outer quadrant of
the left breast. The patient underwent bronchoscopy, excisional breast biopsy and medical thoracoscopy. By cytol-
ogy, histology and immunohistochemistry primary lung adenocarcinoma with metastasis to the breast and parietal
pleura was diagnosed. Both the primary and metastatic anatomic sites demonstrated histologically extensive micro-
papillary component, which is recently recognized as an important prognostic factor. The patient received che-
motherapy but passed away within 7 months. Accurate differentiation of metastatic from primary carcinoma is of
crucial importance because the treatment and prognosis differ significantly.
Background
The National Cancer Institute of the U.S.A. estimates,
that based on current rates, 12.7% of women born today
will be diagnosed with breast cancer in their life time
[1]. Although, primary breast cancer is the most com-
mon malignancy of adult females, metastatic involve-
ment of the breast is rare with a reported frequency of
0.4 - 1.3% in clinical series [2-5]. Despite its rarity,
metastatic disease to the breast is an important diagnos-
tic clinical dilemma, because its treatment differs greatly
from that of primary breast cancer.
Sitzentfrey, in 1907, was the first to publish a case of
ovarian carcinoma metastatic to the breast [6]. Since
then a wide variety of malignancies have been reported
to metastasize to the breast and according to the litera-
ture the most common primary tumors are melanomas
and haematological malignancies [5,7]. Despite the fact
that the lung is the most common cancer site in terms
of incidence and mortality there are only few published
cases on pulmonary carcinomas metastasizing to the
breast [8-12].
Carcinomas with micropapillary components have
been reported at several anatomical sites, including the
breast, urinary bladder, ovary and major salivary glands
[13]. The micropapillary component is being increas-
ingly recognized as a prognostic predictor in lung ade-
nocarcinomas and according to many authors it may be
a manifestation of aggressive behaviour [14,15]. We
report a patient with metastasis to the breast from a
pulmonary adenocarcinoma with extensive micropapil-
lary pattern diagnosed concomitantly with the primary
tumor.
Case Presentation
A 73-year-old, non-smoker, housewife presented to the
emergency department with dyspnea and dry cough of
4 weeks duration. Examination of the chest revealed
reduced breath sounds and percussion dullness at the
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painless, poorly defined mass, associated with skin red-
ness, in the upper outer quadrant of the left breast.
Palpable left axillary lymph nodes were also noted.
A chest radiograph showed massive pleural effusion
occupying most of the left hemithorax (Figure 1a). In
the chest computed tomography (Figure 1b), the left
lung was atelectatic and compressed by massive pleural
effusion.
The mediastinum and the trachea were severely dis-
placed to the right. A few lymph nodes deeply in the
left axilla and some paratracheal lymph nodes were
observed. Clinically the diagnosis was considered to be
either a primary breast tumor with lung and pleural
metastasis or two synchronous primaries. Mammogra-
phy showed diffuse asymmetrical density in the subal-
veolar region and the upper outer quadrant of the left
breast. (Figure1c). Additionally, skin thickening was
demonstrated in the affected area. Calcifications were
not observed. The differential diagnosis included inflam-
mation, lymphoma and inflammatory breast carcinoma.
Excisional biopsy was recommended.
Moreover, the patient underwent bronchoscopy which
revealed submucosal infiltration causing widening of the
secondary carina and obstruction of the orifice of the
lingula at approximately 70%. Pleural effusion re-accumu-
lated rapidly so in order to perform pleural drainage and
chemical pleurodesis medical thoracoscopy was carried
out. During the procedure biopsies were obtained from the
parietal pleura. Chest computed tomography (Figure 1d)
followed and showed a 3,5 × 4,5 cm peripheral lesion, on
the left upper lobe, with relative abnormal contour and
extension into the surrounding parenchyma. The tumor
was in contact to the splanchnic pleura and approached
the parietal pleura, possibly invading it. Finally, an exci-
sional breast biopsy was performed.
Our patient received 4 courses of Bevacizumab,
Cisplatin and Docetaxel with no clinical response.
Unfortunately the patient died 6 months following
diagnosis.
Cytologic and Immunocytochemical findings
All cytologic specimens were stained by the Papanico-
laou technique and evaluated by cytology. By examining
the pleural effusion (Figure2 a ,b ) ,b r o n c h i a lw a s h i n g
(BW)s and bronchial brush (BB) specimens the diagno-
sis of adenocarcinoma was achieved. By immunocyto-
chemistry performed on smears prepared from the
pleural effusion sample, tumor cells were strongly
immunoreactive for thyroid transcription factor-1
(TTF-1) (Figures 2c, d) and monoclonal CEA. Tumour
cells were negative for CK 5/6, estrogen receptors (ER),
CA-125 and thyroglobulin (Table 1).
Histopathological and Immunohistochemical findings
Hematoxylin - Eosin (H&E) stained paraffin sections of
the bronchoscopy biopsy demonstrated bronchial muco-
sal infiltration by a low differentiated adenocarcinoma.
An extensive micropapillary component was identified
Figure 1 Imaging techniques.a )Chest x-ray: Massive pleural
effusion occupying most of the left hemithorax with evident
displacement of the mediastinum to the right (blue arrow). b) Chest
computed tomography: The left lung is atelectatic and compressed
by massive pleural effusion (red arrow). The mediastinum and the
trachea are severely displaced to the right. A few lymph nodes can
be seen, deeply in the left axilla. Additionally, some paratracheal
lymph nodes can be observed (yellow arrow). c) Chest computed
tomography: A 3,5 × 4,5 cm peripheral lesion, on the left upper
lobe, with relative abnormal contour and extension into the
surrounding parenchyma. The tumor is in contact to the splanchnic
pleura and approached the parietal pleura, possibly invading it
(green arrow). d) Digital mammography: Diffuse asymmetrical
density in the subalveolar region and the upper outer quadrant of
the left breast.
Figure 2 Pleural effusion aspiration smears.a )C l u s t e r so f
malignant cells with morphological features of adenocarcinoma
(Papanicolaou stain, ×400). b) Clusters of malignant cells with
morphological features of adenocarcinoma (Papanicolaou stain,
×600). c) Immunocytochemical positivity to TTF-1 (×350). d)
Immunocytochemical positivity to TTF-1 (×280).
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tures with tufts that lacked a central fibrovascular core.
Additionally, occasional psammoma bodies were noted.
Our differential diagnosis included primary lung adeno-
carcinoma, metastatic adenocarcinoma from the
thyroid, the breast or the ovary and finally metastatic -
epithelioid (papillary) type - mesothelioma. The tumor
cells demonstrated immunoreactivity for CD 15 (Leu-
M1), TTF-1, Surfactant protein A (SP-A) and monoclo-
nal CEA. The neoplastic cells lacked expression of gross
cystic disease fluid protein-15 (GCDFP-15), ER, mam-
maglobin, CK 5/6, calretinin, CA-125 and thyroglobulin
(Table 1). Based on the histology and the immunohisto-
chemical staining pattern, a diagnosis of primary lung
adenocarcinoma with micropapillary component was
rendered.
H&E stained paraffin sections of the parietal pleura
biopsies revealed diffuse infiltration by malignant epithe-
lioid type cells, which demonstrated solid and micropa-
pillary pattern. Additionally, numerous psammoma
bodies were observed (Figures 4a, b). Tumor cells
revealed the same immunoprofile as the lung biopsy
(Figures 4c, d).
Finally, the breast biopsy specimen demonstrated
dense fibrohylinized stroma with atrophic terminal duc-
tal lobular units. Within the stroma, sharply demarcated
nodules of a high grade adenocarcinoma with solid and
micropapillary pattern was demonstrated (Figure 5a).
Lymphatic tumor emboli of micropapillary pattern ade-
nocarcinoma with multiple psammoma bodies were also
identified (Figure 5b). The surrounding breast parench-
yma demonstrated mild fibrocytic changes. Finally, no
evidence of in situ carcinoma or elastosis was observed.
Taking into account the diagnosis of the lung and
pleura biopsies our differential diagnosis included a
second primary breast carcinoma and metastatic lung
carcinoma. The tumor cells demonstrated immunoreac-
tivity for TTF-1 (Figure 5c, d), SP-A and lacked expres-
sion of GCDFP-15, ER and mammaglobin (Table 1).
Discussion
Worldwide, lung cancer is the most common cancer in
terms of both incidence and mortality (1.6 million new
cases per year and 1.378 million deaths) [8]. Approxi-
mately one fifth, of newly diagnosed lung adenocarcino-
mas, present with distant metastases. The most common
sites of metastasis are brain, bone, liver, and adrenal
glands, in decreasing order. However autopsy series have
Table 1 Antibodies employed in the
immunohistochemistry applied
Antigen Clone Source, location Dilution
TTF-1 8G7G3/1 Dako, Glostrup, Denmark 1:50
SP-A PE-10 Dako, Glostrup, Denmark 1:20
CEA
monoclonal
II-7 Dako, Glostrup, Denmark 1:50
ERa 1D5 Dako, Glostrup, Denmark 1:30
GCDFP-15 23A3 NeoMarkers, Fremont, CA,
USA
Prediluted
Mammaglobin 304-1A5 Dako, Glostrup, Denmark 1:100
CK 5/6 D5/16B4 Dako, Glostrup, Denmark 1:50
Calretinin DAK-
Calret 1
Dako, Glostrup, Denmark 1:100
CA-125 M11 Dako, Glostrup, Denmark 1:100
Thyroglobulin DAK-Tg6 Dako, Glostrup, Denmark 1:100
CD 15 MMA NeoMarkers, CA, USA Prediluted
TTF-1, thyroid transcription factor-1; SP-A, surfactant apoprotein A; CEA,
carcinoembryonic antigen; GCDFP-15, gross cystic disease fluid protein-15; ER,
estrogen receptor.
Figure 3 Bronchoscopy biopsy. Low differentiated adenocarcinoma
with micropapillary component (arrow). (Hematoxylin-eosin, ×100).
Figure 4 Parietal pleural biopsy. a) Infiltration by adenocarcinoma
with micropapillary pattern (single arrow). Multiple psammoma
bodies are observed (double arrow). (Hematoxylin-eosin, ×100). b)
Infiltration by adenocarcinoma with micropapillary pattern.
(Hematoxylin-eosin, ×400). c) Immunohistochemical nuclear TTF-1
positivity of malignant cells. (×400). d) Immunohistochemical
cytoplasmic SP-A positivity of malignant cells. (×400).
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organ.
Breast metastases from extra-mammary malignancies
are rare accounting for 0.4 to 1.3% of all breast malig-
nancies [2-5]. Nearly 700 cases have been reported in
small series and case reports [2-5,7,12,16,17].
According to the international literature the most
common sources of primary tumors were haematologi-
cal malignancies, malignant melanoma, lung tumors,
renal cell carcinoma, ovarian tumors, thyroid carcino-
mas and small bowel carcinoids [3,7,17]. Williams et al
in the largest published series of 169 cases with metas-
tases to the breast from extramammary solid tumors
reported that the most common histological type was
malignant melanoma [7].
Review of the literature (1990-2010) includes approxi-
mately 30 NSCLCs as case reports or part of a series of
secondary breast tumors [4,5,9-12,18-26]. Twelve of
the above cases were classified as adenocarcinomas
[5,9,12,18,20-22,24]. Additionally, 53 cases of breast
metastasis from lung tumors were presented however,
no detailed histological classification was provided
[7,17,27-29]. The majority of breast metastases present
as palpable, rapidly growing, well circumscribed, painless
breast masses with predilection to the upper outer
quadrant [2,7,12,16,21]. Unlike primary tumors, in the
vast majority of metastases retraction of the skin or nip-
ple is not demonstrated despite their superficial location
[5,21]. However, in our patient, the lesion was poorly
defined and skin redness was observed. Other authors
have rarely reported similar findings [7,16,24,29].
Distinguishing a breast metastasis from a primary
mammary adenocarcinoma, based on mammographic
findings, may be extremely difficult because of the wide
range of imaging manifestations of the metastatic lesion
[4,5,17]. Thus, metastasis can mimic a primary malignancy
or even a benign breast tumor [4,5,17]. The most com-
monly described mammographic presentation is usually
single but sometimes multiple well circumscribed lesions
with smooth margins [3,17,29]. Microcalcifications are
very uncommon but have been reported in patients with
metastatic serous ovarian papillary carcinoma [17,28,29].
In our case, mammography showed diffuse asymmetrical
density and skin thickening. In cases such as ours the dif-
ferential diagnosis includes inflammation, lymphoma and
inflammatory breast carcinoma.
As sited in the literature, histological features that may
aid in the recognition of secondary tumors are the fol-
lowing: The absence of in situ carcinoma strongly sup-
ports a metastatic tumor, although it may not be present
in all primary invasive carcinomas. Additionally, meta-
static malignancies are often sharply circumscribed from
the surrounding breast tissue. Furthermore, elastosis is
common in primary tumors but rare in extramammary
malignancies [2,4,5,12,18]. Occasionally, metastases to
the breast demonstrate features that can lead pathologists
to the correct diagnosis such as presence of pigmentation
and intranuclear inclusions in malignant melanomas.
Nevertheless, many extramammary malignancies such as
adenocarcinoma of the lung lack specific histological
features.
Carcinomas with a micropapillary component have
been described in many organs including the breast, urin-
ary bladder, ovary and salivary glands [13]. Amin et al. in
2002, was the first to report lung adenocarcinomas with
micropapillary component [14]. Histologically, the latter
is characterized by small papillary tufts lying freely within
alveolar spaces or encased within the thin walls of con-
nective tissue. These small, cohesive nests lack fibrovas-
cular connective tissue cores [14]. In our case all biopsies
examined demonstrated an extensive micropapillary
component. Although psammoma bodies have not been
observed in invasive micropapillary pattern carcinoma of
t h eu r i n a r yb l a d d e ra n ds a l i v a r yg l a n d st h e yh a v er a r e l y
been reported in cases of lung adenocarcinoma with
micropapillary morphology [13,14,30]. Multiple psam-
moma bodies were demonstrated in the tissue sections of
our samples examined. To the best of our knowledge this
is the first report of a breast metastasis from lung adeno-
carcinoma with micropapillary pattern diagnosed conco-
mitantly with the primary tumor.
The distinction between metastasis from lung adeno-
carcinoma, particularly with extensive micropapillary
pattern, and primary mammary adenocarcinoma may
Figure 5 Breast biopsy. a) Nodular infiltration by solid (high grade)
adenocarcinoma. (Hematoxylin-eosin, ×400). b) Lymphatic tumor
emboli of micropapillary pattern adenocarcinoma (single arrow) and
multiple psammoma bodies (double arrow). Ectatic duct is noted in
the left side. (Hematoxylin-eosin, ×100). c) Immunohistochemical
nuclear TTF-1 positivity of adenocarcinoma with solid and
micropapillary component. (×100). d) Immunohistochemical nuclear
TTF-1 positivity of micropapillary component. (×400).
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of immunohistochemstry to the correct diagnosis is
crucial.
TTF-1 is expressed in 68-80% of lung adenocarcinomas,
and besides a single case published by Klingen TA et al,
has never been reported to stain positive in breast adeno-
carcinoma [31-33]. The sensitivity of SP-A is substantially
less. It is expressed in approximately 45% of lung adeno-
carcinomas [32,33]. A negative expression of thyroglobulin
excludes the diagnosis of papillary carcinoma of the thyr-
oid, which stains positive to both markers. ERs are
expressed in 80% and GCDFP-15 in 45-53% of breast car-
cinomas [32,34]. As recently published, ER expression in
the lung adenocarcinoma, by using the monoclonal anti-
bodies 1D5 and 6F11 is low (7,6-14,1%) [32,35]. Addition-
ally, 5,2-15% of lung adenocarcinomas express GCDFP-15
[34,36]. Finally, mammaglobin is expressed in 48-72,1% of
mammary adenocarcinomas but stains negative in pul-
monary adenocarcinomas [32,34,37]. Consequently, a
panel of markers must be used as no single antibody is
100% sensitive and false negative results do occur. In our
case, all the tumor specimens (lung, pleura and breast)
showed positive nuclear staining for TTF-1 and cytoplas-
mic staining for SP-A. The neoplastic cells lacked expres-
sion of GCDFP-15, ER and mammaglobin.
Overall metastasis to the breast has been associated
with poor prognosis with most patients dying within a
year of diagnosis [7]. Our patient survived 6 months fol-
lowing the diagnosis of both the primary lung tumor
and the breast metastasis.
Conclusions
We reported a rare case of metastasis to the breast from
an adenocarcinoma of the lung with extensive micropa-
pillary component. Metastatic disease to the breast,
although rare, should be considered in the differential
diagnosis of a primary mammary carcinoma because the
treatment and prognosis differ significantly. Further-
more, the distinction between metastasis from lung ade-
nocarcinoma, particularly with extensive micropapillary
pattern, and primary breast adenocarcinoma may cause
a significant diagnostic dilemma. The contribution of
immunohistochemstry to the correct diagnosis is very
important.
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